Global Chronic Liver Diseases Therapeutics Market
In 2015, according to the National Survey on Drug Use and Health (NSDUH) data, around 88,000 people (around 62,000 men and 26,000 women) died due to alcohol-related causes annually, which makes alcohol consumption the fourth leading preventable cause of death in the U.S. Such rise in prevalence of liver disease is driving growth of the chronic liver diseases therapeutics market.
Similarly, the high number of patients with chronic liver disease such as cirrhosis is significantly contributing to the growth of the global chronic liver disease therapeutic market. For instance, in 2016, around 4.5 million adults were diagnosed with cirrhosis liver disease, out of which, 12.8 deaths occurred per 100,000 people. This is expected to drive growth of the global chronic liver disease therapeutics market.
๐๐จ ๐๐๐ญ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฐ๐ข๐ญ๐ก ๐๐๐ญ๐๐ฌ๐ญ ๐๐จ๐ฏ๐ข๐๐๐ ๐๐ฆ๐ฉ๐๐๐ญ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ข๐ฌ @ https://www.coherentmarketinsights.com/insight/request-sample/4047
Global Chronic Liver Diseases Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
The spread of coronavirus has negatively impacted the global chronic liver disease therapeutics market. The outbreak of this virus has hindered the growth of the global market. The U.S has the highest number of corona patients which is expected to impact the countryโs economic condition. The U.S is high potential market for the pharmaceuticals industry, and the economic slowdown of the U.S economy is likely to impact the market for pharmaceutical drugs. Similarly, markets in India, Brazil, Russia and other economies are also suffering due to Covid-19 attack that is expected to impact on lowering the pharmaceutical growth.ย Furthermore, due to COVID-19 pandemic, hospitals are closed in containment zones, that has slowed the hospital visits and stabilized the demand for therapeutic drugs of chronic liver diseases.
The global chronic liver diseases therapeutics market is estimated to be valued atย US$ 12.8 Bn in 2020ย and is expected to exhibit aย CAGR of 9.7%ย during the forecast periodย (2020-2027).
Global Chronic Liver Diseases Therapeutics Market – Restraints
Side effects and risks associated with consumption of such drugs are projected to hinder growth of the global liver disease therapeutics market. The side effects such as nausea, headache, fever loss of appetite, and drug-induced liver disease are usually occur due to consumption of liver disease drug. Moreover, availability of alternate treatment procedures such as organ transplantation and liver resection are also projected to restrict growth of the market.
Global Chronic Liver Diseases Therapeuticsย Market: Opportunities
Growing research and development of immunotoxins is projected to provide lucrative growth opportunities to players operating in the global chronic liver disease therapeutics market. For instance, GPC3 is a cell surface heparan sulfate proteoglycan that is overexpressed in hepatocellular carcinoma. Anti-GPC3 immunotoxins can be effective in the treatment of human hepatocellular carcinoma.
Moreover, clinical trials of new therapies are again projected to support market growth. For instance, in March 2018, the U.S. FDA granted Orphan Drug Designation for Protagonist Therapeutics, Inc.โs PTG-300; a subcutaneous injectable in clinical development stage for the potential treatment of beta-thalassemia and liver fibrosis.
๐๐ฎ๐ฒ ๐๐จ๐ฐ ๐๐ง๐ ๐๐๐ญ ๐ ๐ฅ๐๐ญ ๐๐% ๐๐ข๐ฌ๐๐จ๐ฎ๐ง๐ญ
๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ก๐ข๐ฌ ๐๐ซ๐๐ฆ๐ข๐ฎ๐ฆ ๐๐๐ฉ๐จ๐ซ๐ญ ๐๐จ ๐๐๐๐๐ฌ๐ฌ ๐ ๐ฎ๐ฅ๐ฅ ๐๐ง๐๐จ๐ซ๐ฆ๐๐ญ๐ข๐จ๐ง @ https://www.coherentmarketinsights.com/insight/buy-now/4047
Global Chronic Liver Diseases Therapeutics Market โ Regional Analysis
On the basis of region, the global chronic liver disease therapeutics market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
The market in North America is expected to witness significant growth owing to presence of major players in the region. Players are focused on partnership strategies to expand their product portfolio. For instance, in April 2020, Alnylam Pharmaceuticals, Inc. collaborated with Dicerna Pharmaceuticals, Inc. for development and commercialization of investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease.
Asia Pacific is projected to experience significant growth over the forecast period owing to high disease prevalence in the region. For instance, according to the NCBI (National Center for Biotechnology Information), Asia Pacific accounted for 62.6% of global deaths due to liver disease in 2015.
Europe is also projected to experience growth in the global chronic liver disease therapeutics market due to increased prevelence of liver diseased population in European countries. For instance, according to data published by the UK Research Alcohol Association in 2017, around 7,700 people die from alcohol-related liver disease each year in the U.K.
Global Chronic Liver Diseases Therapeutics Market – Competitive Landscape
Key players operating in the global chronic liver disease therapeutics market are Astellas Pharma Inc., Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Pfizer Inc., Takeda Pharmaceutical, Valeant Pharmaceuticals, Watson Pharmaceuticals, Inc., Theratechnologies Inc., Alnylam Pharmaceuticals, Inc., Protagonist Therapeutics, Inc., Dicerna Pharmaceuticals, Inc., Endo International, Provectus Biopharmaceuticals Inc., and MAX BioPharma, Inc.
๐๐จ ๐๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ ๐๐ซ๐จ๐๐ก๐ฎ๐ซ๐ ๐๐๐ซ๐ @ https://www.coherentmarketinsights.com/insight/request-pdf/4047
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Key Developments
- Impact Analysis
- Regulatory Scenario
- Reimbursement Scenario
- New Drug Launches/Approvals
- Mergers & Acquisitions
- PEST Analysis
- Market Dynamics
- Global Chronic Liver Diseases Therapeutics Market, by COVID-19 impact analysis
- Pre COVID Impact
- Post COVID Impact
- Government Initiative
- Global Chronic Liver Diseases Therapeutics Market, By Therapy Type, 2016 โ 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 โ 2027
- Segment Trends
- Anti-Rejection Drugs/ Immunosuppressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Chemotherapy Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Targeted therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Anti-Viral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Immunoglobulins
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Introduction
- Global Chronic Liver Diseases Therapeutics Market, By Distribution Channel, 2016 โ 2027, (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017 โ 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 โ 2027, (US$ Million)
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/chronic-liver-diseases-therapeutics-market-3308
About US:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
